hcre_10k.htm

0001477932-16-010545.txt : 20160523 0001477932-16-010545.hdr.sgml : 20160523 20160523133615 ACCESSION NUMBER: 0001477932-16-010545 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160523 DATE AS OF CHANGE: 20160523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hemcare Health Services Inc. CENTRAL INDEX KEY: 0001420368 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PERSONAL SERVICES [7200] IRS NUMBER: 208248213 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-148546 FILM NUMBER: 161668515 BUSINESS ADDRESS: STREET 1: 4830 W. KENNEDY BLVD. STREET 2: SUITE 600 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: (844) 44362273 MAIL ADDRESS: STREET 1: 4830 W. KENNEDY BLVD. STREET 2: SUITE 600 CITY: TAMPA STATE: FL ZIP: 33609 FORMER COMPANY: FORMER CONFORMED NAME: NSU Resources Inc DATE OF NAME CHANGE: 20140508 FORMER COMPANY: FORMER CONFORMED NAME: Bio-Carbon Solutions International Inc. DATE OF NAME CHANGE: 20110311 FORMER COMPANY: FORMER CONFORMED NAME: Elemental Protective Coating Corp. DATE OF NAME CHANGE: 20100121 10-K 1 hcre_10k.htm FORM 10-K hcre_10k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015

Commission File Number: 333-148546

HEMCARE HEALTH SERVICES INC.

(FORMERLY NSU RESOURCES INC)

(Exact name of registrant as specified in its charter)

NEVADA		20-8248213
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4830 W. Kennedy Blvd., Suite 600, Tampa, FL 33609

(Address of principal executive offices, including zip code)

(844) 4-HEMCARE, (844) 4-436-2273

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

None

Title of class		Name of each exchange on which registered
Common Stock. $0.001 par value per share		None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in 405 of the Securities Act. Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes x No o

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller Reporting Company	x
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 23, 2016 the issuer had 142,162,211 shares of common stock issued and 141,782,211 shares of common stock outstanding.

INDEX

HEMCARE HEALTH SERVICES, INC.

(FORMERLY NSU RESOURCES INC)

		PAGE NO
PART I

ITEM 1	BUSINESS	3
ITEM 1A	RISK FACTORS	4
ITEM 1B	UNRESOLVED STAFF COMMENTS	8
ITEM 2	PROPERTIES	8
ITEM 3	LEGAL PROCEEDINGS	8
ITEM 4	SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS	8

PART II

ITEM 5	MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	9
ITEM 6	SELECTED FINANCIAL DATA	9
ITEM 7	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	10
ITEM 7A	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	11
ITEM 8	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	11
ITEM 9	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	11
ITEM 9A(T)	CONTROLS AND PROCEDURES	11
ITEM 9B	OTHER INFORMATION	13

PART III

ITEM 10	DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	14
ITEM 11	EXECUTIVE COMPENSATION	15
ITEM 12	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	16
ITEM 13	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	16
ITEM 14	PRINCIPAL ACCOUNTANT FEES AND SERVICES	16

PART IV

ITEM 15	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	17

SIGNATURES		18

PART I.

Cautionary Note

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements about our business strategy, the effect of Generally Accepted Accounting Principles ("GAAP") pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds and all plans, objectives, expectations and intentions and the statements regarding future potential revenue, gross margins and our prospects for fiscal 2009. These statements appear in a number of places and can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "future," "intend," or "certain" or the negative of these terms or other variations or comparable terminology, or by discussions of strategy.

Actual results may vary materially from those in such forward-looking statements as a result of various factors that are identified in "Item 1A.—Risk Factors" and elsewhere in this document. No assurance can be given that the risk factors described in this Annual Report on Form 10-K are all of the factors that could cause actual results to vary materially from the forward-looking statements. References in this Annual Report on Form 10-K to (i) the "Company," the "Registrant," "Hemcare Health Services" "we," "our," "HCRE," and "us" refer to Hemcare Health Services, Inc. (formerly NSU Resrouces, Inc.).

Investors and security holders may obtain a free copy of the Annual Report on Form 10-K and other documents filed by Hemcare Health Services Inc. with the Securities and Exchange Commission ("SEC") at the SEC's website at http://www.sec.gov. Free copies of the Annual Report on Form 10-K and other documents filed by Hemcare Health Services Inc. with the SEC may also be obtained from Hemcare Health Services Inc. by directing a request to Hemcare Health Services Inc., Attention: John Wilkes 3800 Paddock Road, R.R. #5, Claremont, Ontario, Canada L1Y 1A2.

ITEM 1

BUSINESS.

General

Hemcare Health Services Inc. (formerly NSU Resources Inc) ("The Company") was incorporated on January 17, 2007, under the laws of the State of Nevada. The principal offices are located at 4830 W. Kennedy Blvd., Suite 600, Tampa, FL 33609. The telephone number is (844) 4-436-2273. The Company has never declared bankruptcy, it has never been in receivership, and it has never been involved in any legal action or proceedings. Our fiscal year end is December 31.

Description of Business

The Company's business plan and objective is to focus on hemorrhoid medical procedures for which it entered into a license agreement to open hemorrhoid treatment centers and promote the Ultroid Hemorrhoid System globally.

Employees

Currently there are no employees of the Company; however, several other employees will be needed to implement the Company's business plan.

Research and Development Expenditures

Since the time of our incorporation we have not incurred any research or development expenditures.

Business Strategy

During the second quarter of 2014, the Company exited the Rare Earth Elements business. As part of this exit, the Company assigned the exclusive license issued from 1776729 Ontario Corporation, a related party, for rare earth extraction and carbon credit technologies to its former officer for $100, thus terminating the Company's license in the technologies. Additionally, a full and mutual release was signed by the Company and Great Rock Development Corp. pertaining to the rare earth extraction technology use as described in the Company's Form 8K filed on April 29, 2013.

On June 29, 2014 the Company was granted the perpetual exclusive rights to the use of Optimum Performance (a proprietary formulation of a highly potent all-in-one daily feed supplement for the Horse industry. In consideration for the assignment of these rights, the Company will pay a gross sales royalty of 1.5% on future sales and agreed to pre-pay royalties by the issuance of 120,000 Preferred Series A 12% Convertible shares to 2412151 Ontario Limited.

During the year ended December 31, 2015, the Company shifted its business focus to hemorrhoid medical procedures and entered into a license agreement to open hemorrhoid treatment centers and promote the Ultroid Hemorrhoid System globally. In consideration for the transfer of these rights to the Company, it issued 100,000 shares of series A preferred convertible stock.

Reports to Security Holders

We file our quarterly and annual report with the Securities and Exchange Commission (SEC), which the public may view and copy at the Public Reference Room at 100 F Street, N.E. Washington D.C. 20549. SEC filings, including supplemental schedule and exhibits, can also be accessed free of charge through the SEC website www.sec.gov.

ITEM 1A

RISK FACTORS

Factors Affecting Future Operating Results

This Annual Report on Form 10-K contains forward-looking statements concerning our future programs, expenses, revenue, liquidity and cash needs as well as our plans and strategies. These forward-looking statements are based on current expectations and we assume no obligation to update this information, except as required by applicable laws and regulations. Numerous factors could cause actual results to differ significantly from the results described in these forward-looking statements, including the following risk factors.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue activities in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months. As such we may have to cease activities and you could lose your investment.

We currently do not have adequate funds to cover the costs associated with maintaining our status as a Reporting Company.

The Company currently has no cash available. This amount will not be enough to pay the legal, accounting, and filing fees that is required to maintain our status as a reporting company, which is currently estimated at $20,000 for fiscal year 2016. If we can no longer be a reporting company our common stock would no longer be eligible for quotation on the Over-the-Counter Bulletin Board. This would result in there being no public market for an investor to trade our common stock and any investment made would be lost in its entirety.

We lack an operating history and have losses which we expect to continue into the future. As a result, we may have to suspend or cease activities, which would result in a complete loss of any investment made into the Company.

We were incorporated on January 17, 2007 and we have not started our proposed business activities or realized any revenues. We have no operating history upon which an evaluation of our future success or failure can be made. As of December 31, 2015 our net loss since inception is $3,254,352. Based upon current plans, we expect to incur operating losses in future periods. Failure to generate revenues will cause us to suspend or cease activities.

If we are able to complete financing through the sale of additional shares of our common stock in the future, then shareholders will experience dilution.

The most likely source of future financing presently available to us is through the sale of shares of our common stock. Any sale of common stock will result in dilution of equity ownership to existing shareholders. This means that if we sell shares of our common stock, more shares will be outstanding and each existing shareholder will own a smaller percentage of the shares then outstanding. To raise additional capital we may have to issue additional shares, which may substantially dilute the interests of existing shareholders. Alternatively, we may have to borrow large sums, and assume debt obligations that require us to make substantial interest and capital payments.

Because there is currently a limited public trading market for our common stock, you may not be able to resell your stock.

Although our common stock is quoted on the Over-the-Counter Bulletin Board (OTCBB) the market is limited. If a market does not develop there would be no central place, such as stock exchange or electronic trading system to resell your shares.

Because our securities are subject to penny stock rules, you may have difficulty reselling your shares.

Our shares are penny stocks are covered by, and subject to, section 15(g) of the Securities Exchange Act of 1934 which imposes additional sales practice requirements on broker/dealers who sell the Company's securities including the delivery of a standardized disclosure document; disclosure and confirmation of quotation prices; disclosure of compensation the broker/dealer receives; and, furnishing monthly account statements. For sales of our securities, the broker/dealer must make a special suitability determination and receive from its customer a written agreement prior to making a sale. The imposition of the foregoing additional sales practices could adversely affect a shareholder's ability to dispose of his stock.

We are subject to the requirements of section 404 of the Sarbanes-Oxley Act. If we are unable to timely comply with section 404 or if the costs related to compliance are significant, our profitability, stock price and results of operations and financial condition could be materially adversely affected.

We are required to comply with the provisions of Section 404 of the Sarbanes-Oxley Act of 2002, which require us to maintain an ongoing evaluation and integration of the internal controls of our business. We were required to document and test our internal controls and certify that we are responsible for maintaining an adequate system of internal control procedures for the year ended December 31, 2015.

We evaluated our existing controls for the year ended December 31, 2015. Our Chief Executive Officer identified material weaknesses, specifically a poor segregation of duties, in our internal control over financial reporting and determined that we did not maintain effective internal control over financial reporting as of December 31, 2015. The identified material weaknesses did not result in material audit adjustments to our 2015 financial statements; however, uncured material weaknesses could negatively impact our financial statements for subsequent years.

In addition, a material weakness in the effectiveness of our internal controls over financial reporting could result in an increased chance of fraud and the loss of customers, reduce our ability to obtain financing and require additional expenditures to comply with these requirements, each of which could have a material adverse effect on our business, results of operations and financial condition.

Further, we believe that the out-of-pocket costs, the diversion of management's attention from running the day-to-day operations and operational changes caused by the need to comply with the requirements of Section 404 of the Sarbanes-Oxley Act could be significant. If the time and costs associated with such compliance exceed our current expectations, our results of operations could be adversely affected.

There may be conflicts of interest between our management and our non-management stockholders.

Conflicts of interest create the risk that management may have an incentive to act adversely to the interests of other investors. A conflict of interest may arise between our management's personal financial interests and the fiduciary duty to our stockholders. Further, our management's own financial interests may at some point compromise their fiduciary duty to our stockholders. John Wilkes and James Cao, who are the Company's sole officers and a majority of its directors, continue to be involved in businesses that operate and commercialize technologies that are similar or related to the Company's, although those businesses exploit and seek to exploit different applications and opportunities. In addition, although it is anticipated that these individuals will spend significant time and effort developing our business, it is possible that they will be exposed to business or employment opportunities that would conflict with the interests of the Company, or cause them to reduce their efforts on the Company's behalf or to entirely cease working with the Company. If we and any other businesses with which our officers are involved wish to take advantage of the same opportunity, then the officer and director that is affiliated with both companies would abstain from voting upon the opportunity.

Future success is highly dependent on the ability of management to further develop and implement a business plan, and secure customers.

The nature of our operations is highly speculative and there is a consequent risk of loss of your investment. The success of our activities will depend on the availability of finances, opportunities relating to carbon trading, offset and reduction regimes, greenhouse gas emission reduction programs, government regulations and economic conditions in the forestry and timber industries. As we have no operating history or revenue and only minimal assets, there is a risk that we will be unable to consummate a business combination. The Company has had no recent operating history and no revenues or earnings from operations since inception. We have no significant assets or financial resources. We will, in all likelihood, sustain operating expenses without realizing significant revenues for the foreseeable future, at least until the market opportunities for the Company's services and technology develops and the demand for our services becomes more proven and regular. This will likely result in our incurring net operating losses for the foreseeable future. We cannot assure that our business will develop as hoped, or that it will become profitable.

Our business may have no revenues for the foreseeable future.

We have had no revenues from operations. Although the technologies offer potential, we may not realize any revenues unless and until we successfully develop a revenue stream from the use of existing licenses.

We may issue more shares to raise additional capital, and permit the development of the Company's business.

As a result, the shareholdings of current shareholders may be diluted. Our Articles of Incorporation authorizes the issuance of a maximum of 275,000,000 shares of common stock. We may issue additional shares from time to time to raise the capital that we anticipate will be required to further develop our business. Any share issuance would be subject to compliance with applicable securities laws and subject to that limitation, unless our Articles of Incorporation are amended with approval of our stockholders. This may result in substantial dilution in the percentage of our common stock held by our then existing stockholders. Moreover, the common stock issued from time to time may be valued on an arbitrary or non-arm's-length basis by our management, resulting in an additional reduction in the percentage of common stock held by our then existing stockholders. Our Board of Directors has the power to issue any or all of such authorized but unissued shares without stockholder approval. To the extent that additional shares of common stock or preferred stock are issued, dilution to the interests of our stockholders will occur and the rights of the holders of common stock might be materially and adversely affected.

There is limited public market for our Common Stock, and we have never paid dividends on our Common Stock.

There is limited public trading market for our common stock which is listed on OTCQB: HCRE and none is expected to develop until our business develops further. Additionally, we have never paid dividends on our common stock and do not presently intend to pay any dividends in the foreseeable future. We anticipate that any funds available for payment of dividends will be re-invested into the Company to further its business strategy. Moreover, a significant number of unregistered securities may not become traded. Pursuant to the Securities Act of 1933, as amended (the "Securities Act") and any other applicable securities laws or regulations these restrictions will limit the ability of our stockholders to liquidate their investment.

Limited Operating History; Need for Additional Capital.

Although the Company draws on the expertise on the principals who have been operating private businesses in the renewable energy and forestry sectors, there is no pertinent historical financial information for the Company upon which to base an evaluation of our performance. Our assets and business have not yet generated substantial or recurring revenues. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services. We will require additional financing to cover costs that we expect to incur over the next twelve months. We believe that debt financing will not be an alternative for funding our operations as we do not have tangible assets to secure any debt financing. We anticipate that additional funding will be in the form of equity financing from the sale of our common stock or other securities. However, we cannot provide any assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our plan of operations. In the absence of such financing, we will not be able to continue and our business plan will fail.

Our common stock is subject to the "penny stock" rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

The Securities and Exchange Commission has adopted certain rules under the Securities Exchange Act of 1934, as amended (the "Exchange Act") that are applicable to "penny stocks". For the purposes relevant to us, a "penny stock" is any equity security that has a market price of less than $5.00 per share or has an exercise or conversion price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require:

·
that a broker or dealer approve a person's account for transactions in penny stocks;

·
the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased; and

·
that a broker or dealer provide certain detailed market information about the market for the applicable company's securities.

In order to approve a person's account for transactions involving penny stocks, the broker or dealer must:

(1) obtain financial information, investment experience and investment objectives of the person; and

(2) make a reasonable determination that the proposed transactions in penny stocks are suitable for that person and that the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prepared by the SEC relating to the penny stock market, which, in highlight form:

·
sets forth the basis on which the broker or dealer made the suitability determination; and

·
that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

Following a transaction, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

Generally, brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for investors to dispose of our common stock and depress the market value of our stock.

There are additional risks of investing in penny stocks whether in public offerings or in secondary trading, relating to commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions.

ITEM 1B

UNRESOLVED STAFF COMMENTS

None

ITEM 2

PROPERTIES.

We do not own any property; the principal offices are located at 4830 W. Kennedy Blvd., Suite 600, Tampa, FL 33609. The telephone number is (844) 4-436-2273.

ITEM 3

LEGAL PROCEEDINGS.

Hemcare Health Services, Inc. is not currently a party to any legal proceedings.

ITEM 4

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None

PART II

ITEM 5

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Our common stock is quoted on the Over-the-Counter Bulletin Board (OTCBB) under the ticker symbol HCRE. The stock trades are limited and sporadic; there is no established public trading market for our common stock.

Dividends

We declared $19,000 of dividends on preferred stock during the year ended December 31, 2015 and anticipate declaring dividends on preferred stock at the same rate during the year ended December 31, 2016.

Securities Authorized for Issuance under Equity Compensation Plans

There is no stock option plan in place for the company.

Recent Sales of Unregistered Securities

There was no sale of unregistered securities during the year ended December 31, 2015.

Securities issued in 2015

During the year ended December 31, 2015, the Company issued a total of 100,000 shares of Series A Preferred Stock in exchange for a prepaid royalty, issued 26,211 common shares as rounding from our 1:50 stock split from March 2015, issued 138,830,000 common shares for the conversion of 138,830 shares of Series A Preferred Stock, rescinded 730,000 common shares and issued 900,000 common shares for cash proceeds of $45,000.

ITEM 6

SELECTED FINANCIAL DATA.

Summary of Financial Data

	December 31, 2015			December 31, 2014
Revenues	$	-		$	-

Operating Expenses	$	399,261		$	26,340

Earnings (Loss)	$	(630,108	)	$	(186,345	)

Total Assets	$	22,964		$	-

Liabilities	$	497,395		$	104,914

Stockholders' Deficit	$	(474,431	)	$	(104,914	)

ITEM 7

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to the results of operations and financial condition of Hemcare Health Serivces Inc. This discussion and analysis should be read in conjunction with our financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Critical Accounting Policies

The preparation of our consolidated financial statements and notes thereto requires management to make estimates and assumptions that affect the amounts and disclosures reported within those financial statements. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contingencies, litigation and income taxes. Management bases its estimates and judgments on historical experiences and on various other factors believed to be reasonable under the circumstances. Actual results under circumstances and conditions different than those assumed could result in differences from the estimated amounts in the financial statements. There have been no material changes to these policies during the year ended December 31, 2015.

Plan of Operations

Liquidity and Capital Resources. As of December 31, 2015 we had cash on hand of $20,334 and we had liabilities of $497,395. We must secure additional funds in order to continue our business. We were required to secure a loan to pay expenses relating to filing this report including legal, accounting and filing fees and may be required to secure additional financing to fund future filings. We believe that we will be able to obtain this loan from a current shareholder of the Company; however we cannot provide any assurance that we will be able to raise additional proceeds or secure additional loans in the future to cover our expenses related to maintaining our reporting company status (estimated at $20,000 for the year ending December 31, 2016). Furthermore, there is no guarantee we will receive the required financing to complete our business strategies; we cannot provide any assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. If we are unable to accomplish raising adequate funds then it would be likely that any investment made into the Company would be lost in its entirety.

Results of Operations. Total operating expenses were $399,261 during the year ended December 31, 2015 compared to $26,340 during the year ended December 31, 2014. The increase in expenses is from the Company incurring increased professional fees associated with broker fees paid for securing the license agreement to distribute the Ultroid Hemorrhoid System.

Other Income (Expense): Other expenses totaled $230,847 during the year ended December 31, 2015 compared to $160,005 during the year ended December 31, 2014. The increase in other expenses is mostly attributable to an increase in excess cost of prepaid royalties over value and $32,177 of interest expenses incurred during the year ended December 31, 2015 on notes entered into during that year.

Off-Balance Sheet Arrangements. None

Contractual Obligations. None

ITEM 7A

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We do not currently hold any market risk sensitive instruments entered into for hedging transaction risks related to foreign currencies. In addition, we have not entered into any transactions with derivative financial instruments for trading purposes.

ITEM 8

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Our financial statements appear beginning on page F-1, immediately following the signature page of this report.

ITEM 9

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None

ITEM 9A(T)

CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

Management of Hemcare Health Services Inc. is responsible for maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 (the "Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

In addition, the disclosure controls and procedures must ensure that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial and other required disclosures.

At the end of the period covered by this report, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Securities Exchange Act of 1934 (the "Exchange Act")) was carried out under the supervision and with the participation of our Principal Executive Officer, Principal Financial and Accounting Officer. Based on his evaluation of our disclosure controls and procedures, he concluded that during the period covered by this report, such disclosure controls and procedures were not effective to detect the inappropriate application of US GAAP standards. This was due to deficiencies that existed in the design or operation of our internal control over financial reporting that adversely affected our disclosure controls and that may be considered to be "material weaknesses."

The Company will continue to create and refine a structure in which critical accounting policies and estimates are identified, and together with other complex areas, are subject to multiple reviews by accounting personnel. In addition, the Company will enhance and test our year-end financial close process. Additionally, the Company's management will increase its review of our disclosure controls and procedures. Finally, we plan to designate individuals responsible for identifying reportable developments. We believe these actions will remediate the material weakness by focusing additional attention and resources in our internal accounting functions. However, the material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Management's Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2015. This assessment is based on the criteria for effective internal control described in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its assessment, management concluded that our internal control over financial reporting as of December 31, 2015 was not effective in the specific areas described in the "Disclosure Controls and Procedures" section above and as specifically described in the paragraphs below.

As of December 31, 2015 the Principal Executive Officer/Principal Financial Officer identified the following specific material weaknesses in the Company's internal controls over its financial reporting processes:

·
Policies and Procedures for the Financial Close and Reporting Process — Currently there are no policies or procedures that clearly define the roles in the financial close and reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Failure to have such policies and procedures in place amounts to a material weakness to the Company's internal controls over its financial reporting processes.

·
Representative with Financial Expertise — For the year ending December 31, 2015, the Company did not have a representative with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures of the Company. Failure to have a representative with such knowledge and expertise amounts to a material weakness to the Company's internal controls over its financial reporting processes.

·
Adequacy of Accounting Systems at Meeting Company Needs — The accounting system in place at the time of the assessment lacks the ability to provide high quality financial statements from within the system, and there were no procedures in place or built into the system to ensure that all relevant information is secure, identified, captured, processed, and reported within the accounting system. Failure to have an adequate accounting system with procedures to ensure the information is secure and accurately recorded and reported amounts to a material weakness to the Company's internal controls over its financial reporting processes.

·
Segregation of Duties — Management has identified a significant general lack of definition and segregation of duties throughout the financial reporting processes. Due to the pervasive nature of this issue, the lack of adequate definition and segregation of duties amounts to a material weakness to the Company's internal controls over its financial reporting processes.

In light of the foregoing, once we have the adequate funds, management plans to develop the following additional procedures to help address these material weaknesses:

·
The Company will create and refine a structure in which critical accounting policies and estimates are identified, and together with other complex areas, are subject to multiple reviews by accounting personnel. In addition, we plan to enhance and test our month-end and year-end financial close process. Additionally, our audit committee will increase its review of our disclosure controls and procedures. We also intend to develop and implement policies and procedures for the financial close and reporting process, such as identifying the roles, responsibilities, methodologies, and review/approval process. We believe these actions will remediate the material weaknesses by focusing additional attention and resources in our internal accounting functions. However, the material weaknesses will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management's report in this annual report.

This report shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting that occurred during our fiscal year ended December 31, 2015 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

ITEM 9B

OTHER INFORMATION.

None.

PART III

ITEM 10

DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

The Company's executive officers and directors and their respective age as of December 31, 2015 are as follows:

Directors:

Name of Director		Age
James Cao		52
John Wilkes		54

Executive Officer:

Name of Officer	Age	Officer
James Cao	52	President and CEO
John Wilkes	54	Chief Financial Officer, Secretary and Treasurer

The term of office for each director is one year, or until the next annual meeting of the shareholders.

Biographical Information

Set forth below is a brief description of the background and business experience of our officers and director for the past year.

James Cao

Mr. James Cao, (52) has 20+ years of experience operating business enterprises, including business to business and business to consumer activities.

Mr. Cao has owned and operated CAO Real Estate, a Commercial and Residential Real Estate Brokerage Firm since 2004. Duties include hiring, training and managing sales associates as well as managing company production and establishing company guidelines and policy and holds a Florida Real Estate Brokers license.

Prior to founding his real estate company, Mr. Cao was President/C.E.O of American Dreamhome Funding, Inc. from 2002 to 2008. American Dreamhome Funding was a successful mortgage brokerage company serving CitiCorp, Wachovia, Countrywide Funding, AmNet Mortgage, Bank of America, Wells Fargo Bank, SunTrust Bank and World Savings. During this time he led a sales force in Florida and Georgia, growing annual sales to $54 million.

From 1999 to 2000 Mr. Cao was the Chief Operating Officer of Netoy Corp. Netoy was a publically traded e-commerce toy company with a $250 million market cap. He was responsible for recruiting, hiring, and successfully expanding their sales force. Mr. Cao negotiated with companies such as IBM, EMC, Oracle and Sprint which allowed them to implement logistical software and hardware to accommodate increased e-commerce traffic.

John Wilkes

Mr. Wilkes, M.B.A., C.P.A., C.A. (54) earned his C.A. designation with Price Waterhouse in Toronto, Canada. Upon obtaining his designation he worked privately for a brief period of time before joining Coopers & Lybrand in Toronto, Canada. While there Mr. Wilkes focused on insolvency and Mergers and Acquisitions. In the early '90's Mr. Wilkes joined a junior investment bank called Pagun Corporation where he spent most of his time evaluating environmental technologies. Since 2005, Mr. Wilkes has been an Independent Investment Management Professional, making private investments in both private and public companies that, for the most part, have their core business in the environmental space.

Significant Employees

We do not employ any non-officers who are expected to make a significant contribution to its business.

Corporate Governance

Nominating Committee. We have not established a Nominating Committee because of our limited operations; and because we have only two directors and one officer, we believe that we are able to effectively manage the issues normally considered by a Nominating Committee.

Audit Committee. We have has not established an Audit Committee because of our limited operations; and because we have only two directors and one officer, we believe that we are able to effectively manage the issues normally considered by a Audit Committee.

Code of Ethics. We have not adopted a Code of Ethics for our principal executive and financial officers.

ITEM 11

EXECUTIVE COMPENSATION.

Summary Compensation Table

Name and principal position	Fiscal Year	Salary		Bonus		Other annual compensation		Restricted stock award(s)		Securities underlying options/ SARs		LTIP payouts		All other compensation

John Wilkes Director	2015		0		0		0		0		0		0		0

James Cao Chief Executive Officer	2015		0		0		0		0		0		0		5,540

There has been no cash payment outside of the amounts above paid to the individuals above for services rendered in all capacities to us for the year ended December 31, 2015. Minimal compensation is anticipated within the next six months to any officer or director of the Company.

Stock Option Grants

We did not grant any stock options to the executive officer during the year ended December 31, 2015.

ITEM 12

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table provides the names and addresses of each person known to the Company to own more than 5% of the outstanding common stock as of December 31, 2015 and by the officers and directors, individually and as a group. Except as otherwise indicated, all shares are owned directly.

Beneficial Owner	Amount of Stock Owned		% Ownership

Tom Krutulis		22,832,000		16.1	%

Jaswinder Singh		12,215,000		8.6	%

Gilles Trahan		10,530,000		7.4	%

Tran Tran		10,000,000		7.0	%

All Others		86,585,211		60.9	%

Total issued		142,162,211		100	%

ITEM 13

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

During the year ended December 31, 2015, there were no other material transactions between the Company and any Officer, Director or related party that has not been disclosed in footnote 5 to the financial statements. Additionally, there are no Officers, Directors or other related parties that since the date of incorporation, had any material interest, direct or indirect, in any transaction with us or in any presently proposed transaction that has or will materially affect us:

·
The Officers and Directors;

·
Any person proposed as a nominee for election as a director;

·
Any other person who beneficially owns, directly or indirectly, shares carrying more than 5% of the voting rights attached to the outstanding shares of common stock;

·
Any relative or spouse of any of the foregoing persons who have the same house as such person.

Any future transactions between us and our Officers, Directors, and Affiliates will be on terms no less favorable to us than can be obtained from unaffiliated third parties. Such transactions with such persons will be subject to approval of our Board of Directors.

ITEM 14

PRINCIPAL ACCOUNTANT FEES AND SERVICES.

During the years ended December 31, 2015 and 2014, the Company incurred auditing expenses of approximately $10,375 and $16,125. There were no other audit related services or tax fees incurred.

PART IV

ITEM 15

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

(a)	The following documents have been filed as a part of this Annual Report on Form 10-K.

1.	Financial Statements

	Page

Report of Independent Registered Public Accounting Firm	F-3
Balance Sheets	F-4
Statements of Operations	F-5
Statements of Stockholders' Deficit	F-6
Statements of Cash Flows	F-7
Notes to Financial Statements	F-8-F-12

2.	Financial Statement Schedules.

All schedules are omitted because they are not applicable or not required or because the required information is included in the Financial Statements or the Notes thereto.

Exhibits.

The following exhibits are filed as part of, or incorporated by reference into, this Annual Report:

EXHIBIT
NUMBER
DESCRIPTION
3.1
Articles of Incorporation
3.2
By-Laws
23.1
Consent of Accountant
31.1
SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
101 XBRL Interactive Data Files

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ James Cao		/s/ John Wilkes
James Cao		John Wilkes
President and Chief Executive Officer		Chief Financial Officer, Secretary and Treasurer
(Principal Executive Officer)		(Principal Financial Officer)

May 23, 2016		May 23, 2016

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources Inc.)

Financial Statements

December 31, 2015 and 2014

F-1

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources Inc.)

Financial Statements

December 31, 2015 and 2014

CONTENTS

	Page(s)

Report of Independent Registered Accounting Firm	F-3

Balance Sheets as of December 31, 2015 and 2014	F-4

Statements of Operations for the years ended December 31, 2015 and 2014	F-5

Statement of Changes in Stockholders' Deficit for the years ended December 31, 2015 and 2014	F-6

Statements of Cash Flows for the years ended December 31, 2015 and 2014	F-7

Notes to the Financial Statements	F-8 - F-12

F-2

PRITCHETT, SILER & HARDY, P.C.

CERTIFIED PUBLIC ACCOUNTANTS

A PROFESSIONAL CORPORATION

1438 N. HIGHWAY 89 STE. 130

FARMINGTON, UTAH 84025

_______________

(801) 447-9572 FAX (801) 447-9578

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Hemcare Health Services Inc. (Formerly NSU Resources Inc.)

Tampa, FL

We have audited the accompanying balance sheets of Hemcare Health Services Inc. (Formerly NSU Resources Inc.) as of December 31, 2015 and 2014 and the related statements of operations, stockholders' deficit and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Hemcare Health Services Inc. (Formerly NSU Resources Inc.) as of December 31, 2015 and 2014 and the results of its operations and cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has a net capital deficiency. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note (2). The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

/s/ Pritchett, Siler & Hardy, P.C.

Pritchett, Siler & Hardy, P.C.

Farmington, Utah 84025

May 23, 2016

F-3

HEMCARE HEALTH SERVICES INC.
Balance Sheets

	December 31,
	2015			2014
ASSETS
Current assets
Cash	$	20,334		$	-
Prepaid expenses		2,630			-
Total current assets		22,964			-

Total assets	$	22,964		$	-

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities
Accounts payable and accrued liabilities	$	86,896		$	67,665
Dividends payable		19,000			-
Related party payables		37,249			37,249
Current notes payables		350,000			-
Related party convertible notes payable, net of discounts $10,249 and $0		385			-
Convertible notes payable, net of discounts $12,835 and $0		3,865			-
Total current liabilities		497,395			104,914

Stockholders' deficit
Series A convertible preferred stock, $1.00 par value; 5,000,000 shares authorized, 81,170 and 120,000 and shares issued and outstanding at December 31, 2015 and 2014		81,170			120,000
Common stock, $0.001 par value; 275,000,000 shares authorized; 142,162,211 and 3,136,000 issued; 141,782,211 and 2,756,000 outstanding at December 31, 2015 and 2014		142,162			3,136
Additional paid in capital		2,556,665			2,377,270
Other comprehensive income		24			24
Treasury stock, 380,000 shares		(100	)		(100	)
Accumulated deficit		(3,254,352	)		(2,605,244	)
Total stockholders' deficit		(474,431	)		(104,914	)

Total liabilities and stockholders' deficit	$	22,964		$	-

See accompanying notes to financial statements.

F-4

HEMCARE HEALTH SERVICES INC.
Statements of Operations

Year ended December 31,

2015

2014

Revenue

$ -

$ -

Operating expenses

General and administrative

23,977

-

Professional fees

375,284

26,340

Total operating expenses

399,261

26,340

Other income (expense)

Other income

937

100

Interest expense

(32,177 )

-

Excess cost of prepaid royalties over value

(199,607 )

(160,105 )
Total other income (expense)

(230,847 )

(160,005 )

Net loss

$ (630,108 )

$ (186,345 )

Preferred stock dividends payable

(19,000 )

-

Net loss attributable to common shareholders

$ (649,108 )

$ (186,345 )

Basic and diluted loss per common share

$ (0.01 )

$ (0.06 )

Weighted average shares outstanding

87,783,992

2,932,578

See accompanying notes to financial statements.

F-5

HEMCARE HEALTH SERVICES INC.
Statement of Changes in Stockholders' Deficit

	Preferred Stock						Common Stock						Additional Paid-			Other comprehensive		Treasury			Accumulated
	Shares			Amount			Shares			Amount			in Capital			income		Stock			Deficit			Total

Balance, December 31, 2013		-		$	-			3,136,000		$	3,136		$	2,337,165		$	24	$	-		$	(2,418,899	)	$	(78,574	)

Preferred shares issued for prepayment of royalty		120,000			120,000			-			-			40,105			-		-			-			160,105
Treasury stock exchanged for asset		-			-			(380,000	)		-			-			-		(100	)		-			(100	)
Net loss, year ended December 31, 2014		-			-			-			-			-			-		-			(186,345	)		(186,345	)
Balance, December 31, 2014		120,000			120,000			2,756,000			3,136			2,377,270			24		(100	)		(2,605,244	)		(104,914	)

Preferred shares issued for prepayment of royalty		100,000			100,000			-			-			99,607			-		-			-			199,607
Conversion of preferred shares to common shares		(138,830	)		(138,830	)		138,830,000			138,830			-			-		-			-			-
Issuance of common shares for rounding in stock split								26,211			26			(26	)		-		-			-			-
Recession of common shares		-			-			(730,000	)		(730	)		730			-		-			-			-
Common stock issued for cash		-			-			900,000			900			44,100			-		-			-			45,000
Beneficial conversion features recorded as debt discounts		-			-			-			-			34,984			-		-			-			34,984
Dividend declared on preferred stock		-			-			-			-			-			-		-			(19,000	)		(19,000	)
Net loss, year ended December 31, 2015		-			-			-			-			-			-		-			(630,108	)		(630,108	)
		81,170		$	81,170			141,782,211		$	142,162		$	2,556,665		$	24	$	(100	)	$	(3,254,352	)	$	(474,431	)

See accompanying notes to financial statements.

F-6

HEMCARE HEALTH SERVICES INC.
Statements of Cash Flows

	Year ended December 31,
	2015			2014
Cash flows from operating activities
Net loss from operations	$	(630,108	)	$	(186,345	)
Adjustments to reconcile net loss to net cash used in operating activities
Excess cost of prepaid royalties over value		199,607			160,105
Gain on sale of intangible asset for treasury stock		-			(100	)
Note payable entered into for professional fees		350,000			-
Amortization of debt discounts		11,900			-
Expenses paid on behalf of company by related parties		15,784			18,035
Changes in operating assets and liabilities
Prepaid expenses		(2,630	)		800
Accounts payable and accrued liabilities		19,231			7,505
Net cash provided by (used in) operating activities		(36,216	)		-

Net cash used in investing activities		-			-

Cash flows from financing activities
Proceeds from convertible notes payable		19,700			-
Repayments of convertible notes payable		(3,000	)
Repayments of related party convertible notes payable		(5,150	)
Proceeds from sale of common stock		45,000			-
Net cash provided by financing activities		56,550			-

Net change in cash		20,334			-
Cash at beginning of period		-			-
Cash at end of period	$	20,334		$	-

Supplemental cash flow information
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

Non-cash investing and financing activities
Preferred stock issued for prepaid royalties	$	100,000		$	120,000
Related party convertible notes entered into in exchange for related party payable	$	15,784		$	-
Note payable entered into for professional fees	$	350,000		$	-

See accompanying notes to financial statements.

F-7

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources, Inc.)

Notes to Financial Statements

December 31, 2015 and 2014

Note 1 – Nature of Business

The Company was organized January 17, 2007 (Date of Inception) under the laws of the State of Nevada, as DBL Senior Care, Inc. The Company subsequently changed its name on December 11, 2009 to Elemental Protective Coatings Corp, subsequently changed its name on January 27, 2011 to Bio-Carbon Solutions International, Inc., then to NSU Resources Inc on October 31, 2011 and more recently to HemCare Health Services Inc. on March 2, 2015. The Company produces and distributes a line of all-in-one horse feed supplement.

The former business of the Company was to provide personal care services to elderly, physically disabled or other home-bound individuals suffering infirmity. During the year ended December 31, 2009, the board of directors changed the Company's focus toward the manufacture and sale of fire retardant products. The Company then changed its focus to the licensing of certain technologies related to rare earth minerals mining then to having the exclusive rights to the use of Optimum Performance (a proprietary formulation of a highly potent all-in-one daily feed supplement for the Horse industry. Currently, the Company has shifted its focus to hemorrhoid medical procedures and entered into a license agreement to open hemorrhoid treatment centers and promote the Ultroid Hemorrhoid System globally

Note 2 – Significant Accounting Policies

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash

For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2015 or 2014.

Income taxes

Income taxes are provided for using the liability method of accounting in accordance with FASB ASC Topic 740 (formally SFAS No. 109 "Accounting for Income Taxes"). A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and rates on the date of enactment.

Revenue Recognition

Revenue is recognized when persuasive evidence of an agreement exists, the price is fixed or determinable, goods are delivered or services performed and collectability is reasonably assured. The Company did not generate any revenues during the years ended December 31, 2015 or 2014.

Convertible debt

The Company records a beneficial conversion feature related to the issuance of convertible debts that have conversion features at fixed or adjustable rates. The beneficial conversion feature for the convertible instruments is recognized and measured by allocating a portion of the proceeds as an increase in additional paid-in capital and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features. The beneficial conversion feature will be accreted by recording additional non-cash interest expense over the expected life of the convertible notes.

F-8

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources, Inc.)

Notes to Financial Statements

December 31, 2015 and 2014

Note 2 – Significant Accounting Policies (continued)

Share Based Expenses

The Company complies with FASB ASC Topic 718 Compensation—Stock Compensation, which establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that is based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. FASB ASC Topic 718 primarily focuses on accounting for transactions in which an entity obtains employee services in share-based payment transactions. This statement requires a public entity to expense the cost of employee services received in exchange for an award of equity instruments. This statement also provides guidance on valuing and expensing these awards, as well as disclosure requirements of these equity arrangements. The Company adopted FASB ASC Topic 718 upon formation of the Company and expenses share based costs in the period incurred.

Going concern

The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. Currently, the Company has no cash, no material assets, accumulated losses of $3,428,812, a working capital deficit of $118,891, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern. The Company will be dependent upon the raising of additional capital through placement of our common stock in order to implement its business plan, or merge with an operating company. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The officers and directors have committed to advancing certain operating costs of the Company.

Valuation of Investments in Securities and Securities at fair value – Definition and Hierarchy

FASB ASC 820-10-15 defines fair value, thereby eliminating inconsistencies in guidance found in various prior accounting pronouncements, and increases disclosures surrounding fair value calculations. FASB ASC 820-10-15 establishes a three-tiered fair value hierarchy that prioritizes inputs to valuation techniques used in fair value calculations. The three levels of inputs are defined as follows:

Level 1 – unadjusted quoted prices for identical assets or liabilities in active markets accessible by the Company at the measurement date.

Level 2 – inputs that are observable in the marketplace other than those inputs classified as Level 1.

Level 3 – inputs that are unobservable in the marketplace and significant to the valuation.

The Company has no assets or liabilities that are required to be carried at fair value. Accounts payable and related party payables have fair values that approximate the carrying value due to the short term nature of these instruments.

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not, or are not believed by management to, have a material impact on the Company's present or future consolidated financial statements.

F-9

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources, Inc.)

Notes to Financial Statements

December 31, 2015 and 2014

Note 2 – Significant Accounting Policies (continued)

Net loss per common share

Net loss per share is calculated in accordance with FASB ASC Topic 260 (formerly SFAS No. 128, Earnings Per Share). The weighted-average number of common shares outstanding during each period is used to compute basic loss per share. Diluted loss per share is computed using the weighted average number of shares and dilutive potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised. Basic net loss per common share is based on the weighted average number of shares of common stock outstanding during the periods presented. The Company had 84,668,400 common stock equivalents that were excluded from earnings per share due to the anti-dilutive nature.

Note 3 – Stockholders' Equity

Series A Convertible Preferred Stock

As discussed in the 8-K filed with the SEC on June 29, 2014, during the year ended December 31, 2014, the Company amended its articles of incorporation to designate the previously authorized series A preferred stock to series A convertible preferred stock. The preferred series A 12% convertible shares have a par value of $1, entitle holder to one vote and accrue dividends at 12% per year, paid quarterly. At the option of the holder, the stock can be converted into shares of the Company's common stock. The number of shares to be issued will be determined by dividing the amount of the Series A shares being converted by $0.001.

During the year ended December 31, 2014, the Company issued 120,000 shares of series A convertible preferred stock in exchange for a prepayment of royalties to a related party totaling $120,000. During year ended December 31, 2015, the Company issued 100,000 shares of series A convertible preferred stock in exchange for a prepayment of royalties with a deemed value of $0 due to the undeterminable nature of the true future usable value to the Company. The Company also accepted the conversion notices from certain series A convertible preferred shareholders to convert a total of 138,830 shares of series A preferred stock to 138,830,000 shares of $0.001 par value common stock.

The excess of the value of the preferred shares issued in excess of the value of the prepaid royalties has been expensed as a financing cost.

There were 81,170 and 120,000 shares of series A convertible preferred stock issued and outstanding as of December 31, 2015 and 2014. Additionally, the Company had accrued dividends payable on series A convertible preferred stock totaling $19,000 and $0 at December 31, 2015 and 2014.

Common Stock

On March 2, 2015, the Company effected a 1:50 reverse stock split. The effects of the reverse split are shown retroactively in these financial statements.

The authorized common stock of the Company consists of 275,000,000 shares and carries a par value of $0.001. During the year ended December 31, 2014, the Company bought back 380,000 post-split shares of common stock into treasury from a former officer for $100. The shares are being carried as treasury shares as reflected on the balance sheet.

During the year ended December 31, 2015, the Company rescinded 730,000 common shares previously issued pursuant to certain agreements. The Company determined the holders did not have legal right to the shares as issued.

During the year ended December 31, 2015, the Company issued 138,830,000 common shares from the conversion of 138,830 shares of Series A Preferred Stock.

During the year ended December 31, 2015, the Company issued 900,000 shares of common stock for total cash proceeds of $45,000 and 26,211 shares to account for rounding in our 1:50 stock split as previously discussed.

There were 142,162,211 and 3,136,000 common shares issued and 141,782,211 and 2,756,000 outstanding (post-split) at December 31, 2015 and 2014, respectively.

Note 4 – Income Taxes

We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. Pursuant to FASB ASC Topic 740, when it is more likely than not that a tax asset cannot be realized through future income, the Company must provide an allowance for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carry-forwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carry-forward period.

The sources and tax effects of the temporary differences for the periods presented are as follows:

F-10

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources, Inc.)

Notes to Financial Statements

December 31, 2015 and 2014

Note 4 – Income Taxes (continued)

	December 31, 2015			December 31, 2014
Net operating loss carry forward	$	748,640		$	318,139
Applicable Canadian Federal and Provincial tax rates		26.5	%		26.5	%
Deferred tax asset		198,390			84,307
Valuation allowance		(198,390	)		(84,307	)
Net deferred tax asset	$	-		$	-

This represents an increase in the net operating loss carry forward of $430,501 and $19,869 for the years ended December 31, 2015 and 2014. A reconciliation of income taxes computed at the United States federal statutory rate of 35% to the income tax recorded is as follows:

	December 31, 2015			December 31, 2014

Tax benefit at United States Federal statutory rate (35%)	$	220,538		$	65,221
Differences in U.S. and Canadian tax rates on provision		(36,592	)		(15,839	)
Non-deductible losses-prepaids		(69,862	)		(42,428	)
Increase in valuation allowance		(114,083	)		(6,954	)
Income tax provision	$	-		$	-

This represents an increase in the valuation allowance of $114,083 and $6,954 for the years ended December 31, 2015 and 2014. The Company did not pay any income taxes during the years ended December 31, 2015 or 2014, or since inception.

The net federal operating loss carry forward will begin to expire in 2026. This carry forward may be limited upon the consummation of a business combination under IRC Section 381. Tax years commencing in 2012 remain open for examination by the IRS, where applicable.

Note 5 – Related Party Transactions

During the years ended December 31, 2015 and 2014, the Company received loans from its officers totaling $15,784 and $18,035 to fund operations via expenses paid directly to vendors on behalf of the Company. These loans are non-interest bearing, are due on demand and as such included in current liabilities. Imputed interest has been considered, but determined to be immaterial to the financial statements as a whole.

On August 8, 2015, the Company entered into a convertible note payable for $15,784 in exchange for the related party payable incurred from expenses paid on behalf of the Company. The note carries interest at a rate of 6% per annum, is due on August 24, 2016 and may be converted into common stock of the Company at the option of the noteholder at a rate of $.01 per share. The beneficial conversion feature in the note created a debt discount of $15,784 of which $5,535 was recognized during the year ended December 31, 2015 leaving an unamortized discount of $10,249 as of December 31, 2015 that will be recognized over the remaining life of the note. There was $10,634 of interest plus accrued interest totaling $360 due as of December 31, 2015.

F-11

HEMCARE HEALTH SERVICES INC.

(Formerly NSU Resources, Inc.)

Notes to Financial Statements

December 31, 2015 and 2014

Note 6 – Excess Cost of Prepaid Royalties Over Value

During the year ended December 31, 2014, the Company issued a total of 120,000 preferred shares of $1 par value Series A convertible preferred stock. The shares carried a value of $160,105 resulting in an immediate excess payment over value of $160,105 based on the Company's determination that it may not realize value for the prepayment resulting in a full charge-off to operations for $160,105.

During the year ended December 31, 2015, the Company issued a total of 100,000 preferred shares of $1 par value Series A convertible preferred stock. The shares carried a value of $199,607 resulting in an immediate excess payment over value of $199,607 based on the Company's determination that it may not realize value for the prepayment resulting in a full charge-off to operations for $199,607.

Note 7 – Notes Payable

During the year ended December 31, 2015, the Company entered into a note payable with an unrelated party as a settlement for payment of consulting services provided valued at $350,000. The note carries interest of 9% compounded annually and is due on November 19, 2016. There was $350,000 of principal and $19,504 of accrued interest due as of December 31, 2015. Accrued interest payable is included in "accounts payable and accrued liabilities" on the balance sheet.

Note 8 – Convertible Notes Payable

During the year ended December 31, 2015, the Company entered into a convertible note payable with an unrelated party resulting in net cash proceeds to the Company totaling $19,700. The note is convertible into common stock of the Company at the option of the noteholder at a rate of $0.01 per share. The Company measured the value of the beneficial conversion feature of the note and recorded a discount equal to the face value of the note on the date of issuance. The discount will be recognized ratably over the life of the note through the due date as shown below. A summary of the outstanding convertible note payable as of December 31, 2015 follows:

	Due Date	Principal		Discount			Net Value

Noteholder 1	9/1/2016	$	16,700	$	(12,835	)	$	3,865
Total		$	16,700	$	(12,835	)	$	3,865

Note 9 – Subsequent Events

We have evaluated subsequent events through the date of this filing and determined there are no additional events to disclose.

F-12

EX-31.1 2 hcre_ex311.htm CERTIFICATION hcre_ex311.htm

EXHIBIT 31.1

CERTIFICATION

I, James Cao, Chief Executive Officer, certify that:

(1)	I have reviewed this report on Form 10-K for the annual period ended December 31, 2015 of Hemcare Health Services Inc.;

(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5)	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

	Hemcare Health Services Inc.

Date: May 23, 2016	By:	/s/ James Cao
		James Cao Chief Executive Officer (Principal Executive Officer)

EX-32.1 3 hcre_ex321.htm CERTIFICATION hcre_ex321.htm

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, James Cao, the Chief Executive Officer, and Chief Financial Officer of Hemcare Health Services, Inc hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge, the report on Form 10-K of Hemcare Health Services Inc, for the annual period ended December 31, 2015, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Hemcare Health Services Inc.

/s/ James Cao		/s/ James Cao
James Cao		James Cao
President and Chief Executive Officer		Chief Financial Officer, Secretary and Treasurer
(Principal Executive Officer)		(Principal Financial Officer)

May 23, 2016		May 23, 2016

EX-101.INS 4 hcre-20151231.xml XBRL INSTANCE DOCUMENT 0001420368 2016-05-23 0001420368 2015-12-31 0001420368 2013-12-31 0001420368 us-gaap:PreferredStockMember 2014-01-01 2014-12-31 0001420368 us-gaap:PreferredStockMember 2013-12-31 0001420368 us-gaap:PreferredStockMember 2014-12-31 0001420368 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0001420368 us-gaap:CommonStockMember 2013-12-31 0001420368 us-gaap:CommonStockMember 2014-12-31 0001420368 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001420368 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001420368 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001420368 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0001420368 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0001420368 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001420368 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0001420368 us-gaap:TreasuryStockMember 2013-12-31 0001420368 us-gaap:TreasuryStockMember 2014-12-31 0001420368 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001420368 us-gaap:RetainedEarningsMember 2013-12-31 0001420368 us-gaap:RetainedEarningsMember 2014-12-31 0001420368 2014-01-01 2014-12-31 0001420368 us-gaap:PreferredStockMember 2015-01-01 2015-12-31 0001420368 us-gaap:PreferredStockMember 2015-12-31 0001420368 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001420368 us-gaap:CommonStockMember 2015-12-31 0001420368 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001420368 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001420368 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0001420368 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001420368 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0001420368 us-gaap:TreasuryStockMember 2015-12-31 0001420368 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001420368 us-gaap:RetainedEarningsMember 2015-12-31 0001420368 2015-01-01 2015-12-31 0001420368 2014-12-31 0001420368 hcre:NoteholderOneMember 2015-12-31 0001420368 hcre:NoteholderOneMember 2015-01-01 2015-12-31 0001420368 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001420368 us-gaap:SeriesAPreferredStockMember 2014-12-31 0001420368 us-gaap:SeriesAPreferredStockMember 2015-01-01 2015-12-31 0001420368 us-gaap:SeriesAPreferredStockMember 2014-01-01 2014-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 141782211

380000

81170

120000

0.001

275000000

22964

497395

104914

385

37249

19000

86896

67665

22964

100

2556665

2377270

142162

3136

2932578

87783992

-0.06

-0.01

-186345

-630108

160005

230847

160105 199607

32177

100

937

26340

399261

26340

375284

23977

5535

81170

120000

-3254352

-2605244

2630

3865

350000

-474431

-78574

120000

3136

2337165

2377270

-100

-2418899

-2605244

81170

142162

2556665

-100

-3254352

-104914

12835 0

120000

3136000

2756000

81170

141782211

120000 100000 120000 40105 160105 100000 99607 199607 -138830 138830000 -138830 138830 26211 26 -26 -730000 -730 730

900000

900

44100

45000

34984 34984

3000

The Company was organized January 17, 2007 (Date of Inception) under the laws of the State of Nevada, as DBL Senior Care, Inc. The Company subsequently changed its name on December 11, 2009 to Elemental Protective Coatings Corp, subsequently changed its name on January 27, 2011 to Bio-Carbon Solutions International, Inc., then to NSU Resources Inc on October 31, 2011 and more recently to HemCare Health Services Inc. on March 2, 2015. The Company produces and distributes a line of all-in-one horse feed supplement.   The former business of the Company was to provide personal care services to elderly, physically disabled or other home-bound individuals suffering infirmity. During the year ended December 31, 2009, the board of directors changed the Company's focus toward the manufacture and sale of fire retardant products. The Company then changed its focus to the licensing of certain technologies related to rare earth minerals mining then to having the exclusive rights to the use of Optimum Performance (a proprietary formulation of a highly potent all-in-one daily feed supplement for the Horse industry. Currently, the Company has shifted its focus to hemorrhoid medical procedures and entered into a license agreement to open hemorrhoid treatment centers and promote the Ultroid Hemorrhoid System globally

Series A Convertible Preferred Stock   As discussed in the 8K filed with the SEC on June 29, 2014, during the year ended December 31, 2014, the Company amended its articles of incorporation to designate the previously authorized series A preferred stock to series A convertible preferred stock. The preferred series A 12% convertible shares have a par value of $1, entitle holder to one vote and accrue dividends at 12% per year, paid quarterly. At the option of the holder, the stock can be converted into shares of the Company's common stock. The number of shares to be issued will be determined by dividing the amount of the Series A shares being converted by $0.001.   During the year ended December 31, 2014, the Company issued 120,000 shares of series A convertible preferred stock in exchange for a prepayment of royalties to a related party totaling $120,000. During year ended December 31, 2015, the Company issued 100,000 shares of series A convertible preferred stock in exchange for a prepayment of royalties with a deemed value of $0 due to the undeterminable nature of the true future usable value to the Company. The Company also accepted the conversion notices from certain series A convertible preferred shareholders to convert a total of 138,830 shares of series A preferred stock to 138,830,000 shares of $0.001 par value common stock.   The excess of the value of the preferred shares issued in excess of the value of the prepaid royalties has been expensed as a financing cost.   There were 81,170 and 120,000 shares of series A convertible preferred stock issued and outstanding as of December 31, 2015 and 2014. Additionally, the Company had accrued dividends payable on series A convertible preferred stock totaling $19,000 and $0 at December 31, 2015 and 2014.   Common Stock   On March 2, 2015, the Company effected a 1:50 reverse stock split. The effects of the reverse split are shown retroactively in these financial statements.   The authorized common stock of the Company consists of 275,000,000 shares and carries a par value of $0.001. During the year ended December 31, 2014, the Company bought back 380,000 post-split shares of common stock into treasury from a former officer for $100. The shares are being carried as treasury shares as reflected on the balance sheet.   During the year ended December 31, 2015, the Company rescinded 730,000 common shares previously issued pursuant to certain agreements. The Company determined the holders did not have legal right to the shares as issued.   During the year ended December 31, 2015, the Company issued 138,830,000 common shares from the conversion of 138,830 shares of Series A Preferred Stock.   During the year ended December 31, 2015, the Company issued 900,000 shares of common stock for total cash proceeds of $45,000 and 26,211 shares to account for rounding in our 1:50 stock split as previously discussed.   There were 142,162,211 and 3,136,000 common shares issued and 141,782,211 and 2,756,000 outstanding (post-split) at December 31, 2015 and 2014, respectively.

During the year ended December 31, 2015, the Company entered into a note payable with an unrelated party as a settlement for payment of consulting services provided valued at $350,000. The note carries interest of 9% compounded annually and is due on November 19, 2016. There was $350,000 of principal and $19,504 of accrued interest due as of December 31, 2015. Accrued interest payable is included in "accounts payable and accrued liabilities" on the balance sheet.

During the year ended December 31, 2015, the Company entered into a convertible note payable with an unrelated party resulting in net cash proceeds to the Company totaling $19,700. The note is convertible into common stock of the Company at the option of the noteholder at a rate of $0.01 per share. The Company measured the value of the beneficial conversion feature of the note and recorded a discount equal to the face value of the note on the date of issuance. The discount will be recognized ratably over the life of the note through the due date as shown below. A summary of the outstanding convertible note payable as of December 31, 2015 follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td id="hdcell" style="border-bottom: black 1pt solid; text-align: center">Due Date</td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Discount</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Value</td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Noteholder 1</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">9/1/2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">16,700</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(12,835</td> <td style="vertical-align: bottom; padding-bottom: 0.75pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">3,865</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Total</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">16,700</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">(12,835</td> <td style="vertical-align: bottom; padding-bottom: 2.25pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">3,865</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

We have evaluated subsequent events through the date of this filing and determined there are no additional events to disclose.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents.  There were no cash equivalents as of December 31, 2015 or 2014.

Income taxes are provided for using the liability method of accounting in accordance with FASB ASC Topic 740 (formally SFAS No. 109 "Accounting for Income Taxes").  A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting.  Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and rates on the date of enactment.

Net loss per share is calculated in accordance with FASB ASC Topic 260 (formerly SFAS No. 128, Earnings Per Share). The weighted-average number of common shares outstanding during each period is used to compute basic loss per share. Diluted loss per share is computed using the weighted average number of shares and dilutive potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised. Basic net loss per common share is based on the weighted average number of shares of common stock outstanding during the periods presented. The Company had 84,668,400 common stock equivalents that were excluded from earnings per share due to the anti-dilutive nature.

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not, or are not believed by management to, have a material impact on the Company's present or future consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td id="hdcell" style="border-bottom: black 1pt solid; text-align: center">Due Date</td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Discount</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Value</td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%"> </td> <td style="width: 1%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Noteholder 1</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">9/1/2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">16,700</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(12,835</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">3,865</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Total</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">16,700</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">(12,835</td> <td style="vertical-align: bottom; padding-bottom: 2.05pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">3,865</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

10634

360

120000 100000

142162211

3136000

141782211

2756000

350000

19504

9/1/2016 16700 16700 -12835 -12835 HEMCARE HEALTH SERVICES INC. 0001420368 10-K 2015-12-31 false --12-31 No Yes No Smaller Reporting Company FY 2015 0

19000

-186345

-649108

-380000 -100 -100 -350000

11900

18035 15784

-800

2630

7505

19231

-36216

19700

5150

45000

56550

20334

15784

100

During the year ended December 31, 2014, the Company issued a total of 120,000 preferred shares of $1 par value Series A convertible preferred stock. The shares carried a value of $160,105 resulting in an immediate excess payment over value of $160,105 based on the Company's determination that it may not realize value for the prepayment resulting in a full charge-off to operations for $160,105.   During the year ended December 31, 2015, the Company issued a total of 100,000 preferred shares of $1 par value Series A convertible preferred stock. The shares carried a value of $199,607 resulting in an immediate excess payment over value of $199,607 based on the Company's determination that it may not realize value for the prepayment resulting in a full charge-off to operations for $199,607.

During the years ended December 31, 2015 and 2014, the Company received loans from its officers totaling $15,784 and $18,035 to fund operations via expenses paid directly to vendors on behalf of the Company. These loans are non-interest bearing, are due on demand and as such included in current liabilities. Imputed interest has been considered, but determined to be immaterial to the financial statements as a whole.   On August 8, 2015, the Company entered into a convertible note payable for $15,784 in exchange for the related party payable incurred from expenses paid on behalf of the Company. The note carries interest at a rate of 6% per annum, is due on August 24, 2016 and may be converted into common stock of the Company at the option of the noteholder at a rate of $.01 per share. The beneficial conversion feature in the note created a debt discount of $15,784 of which $5,535 was recognized during the year ended December 31, 2015 leaving an unamortized discount of $10,249 as of December 31, 2015 that will be recognized over the remaining life of the note. There was $10,634 of interest plus accrued interest totaling $360 due as of December 31, 2015.

Revenue is recognized when persuasive evidence of an agreement exists, the price is fixed or determinable, goods are delivered or services performed and collectability is reasonably assured. The Company did not generate any revenues during the years ended December 31, 2015 or 2014.

The Company complies with FASB ASC Topic 718 CompensationStock Compensation, which establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that is based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. FASB ASC Topic 718 primarily focuses on accounting for transactions in which an entity obtains employee services in share-based payment transactions. This statement requires a public entity to expense the cost of employee services received in exchange for an award of equity instruments. This statement also provides guidance on valuing and expensing these awards, as well as disclosure requirements of these equity arrangements. The Company adopted FASB ASC Topic 718 upon formation of the Company and expenses share based costs in the period incurred.

FASB ASC 820-10-15 defines fair value, thereby eliminating inconsistencies in guidance found in various prior accounting pronouncements, and increases disclosures surrounding fair value calculations. FASB ASC 820-10-15 establishes a three-tiered fair value hierarchy that prioritizes inputs to valuation techniques used in fair value calculations. The three levels of inputs are defined as follows:   Level 1 unadjusted quoted prices for identical assets or liabilities in active markets accessible by the Company at the measurement date.   Level 2 inputs that are observable in the marketplace other than those inputs classified as Level 1.   Level 3 inputs that are unobservable in the marketplace and significant to the valuation.   The Company has no assets or liabilities that are required to be carried at fair value. Accounts payable and related party payables have fair values that approximate the carrying value due to the short term nature of these instruments. The Company records a beneficial conversion feature related to the issuance of convertible debts that have conversion features at fixed or adjustable rates. The beneficial conversion feature for the convertible instruments is recognized and measured by allocating a portion of the proceeds as an increase in additional paid-in capital and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features. The beneficial conversion feature will be accreted by recording additional non-cash interest expense over the expected life of the convertible notes.

Estimates   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.   Cash   For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents.  There were no cash equivalents as of December 31, 2015 or 2014.   Income taxes   Income taxes are provided for using the liability method of accounting in accordance with FASB ASC Topic 740 (formally SFAS No. 109 "Accounting for Income Taxes").  A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting.  Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and rates on the date of enactment.   Revenue Recognition   Revenue is recognized when persuasive evidence of an agreement exists, the price is fixed or determinable, goods are delivered or services performed and collectability is reasonably assured. The Company did not generate any revenues during the years ended December 31, 2015 or 2014.   Convertible debt   The Company records a beneficial conversion feature related to the issuance of convertible debts that have conversion features at fixed or adjustable rates. The beneficial conversion feature for the convertible instruments is recognized and measured by allocating a portion of the proceeds as an increase in additional paid-in capital and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features. The beneficial conversion feature will be accreted by recording additional non-cash interest expense over the expected life of the convertible notes.   Share Based Expenses   The Company complies with FASB ASC Topic 718 CompensationStock Compensation, which establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that is based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. FASB ASC Topic 718 primarily focuses on accounting for transactions in which an entity obtains employee services in share-based payment transactions. This statement requires a public entity to expense the cost of employee services received in exchange for an award of equity instruments. This statement also provides guidance on valuing and expensing these awards, as well as disclosure requirements of these equity arrangements. The Company adopted FASB ASC Topic 718 upon formation of the Company and expenses share based costs in the period incurred.   Going concern   The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern.  This contemplates the realization of assets and the liquidation of liabilities in the normal course of business.  Currently, the Company has no cash, no material assets, accumulated losses of $3,428,812, a working capital deficit of $118,891, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern.  The Company will be dependent upon the raising of additional capital through placement of our common stock in order to implement its business plan, or merge with an operating company.  There can be no assurance that the Company will be successful in either situation in order to continue as a going concern.  The officers and directors have committed to advancing certain operating costs of the Company.   Valuation of Investments in Securities and Securities at fair value Definition and Hierarchy   FASB ASC 820-10-15 defines fair value, thereby eliminating inconsistencies in guidance found in various prior accounting pronouncements, and increases disclosures surrounding fair value calculations. FASB ASC 820-10-15 establishes a three-tiered fair value hierarchy that prioritizes inputs to valuation techniques used in fair value calculations. The three levels of inputs are defined as follows:   Level 1 unadjusted quoted prices for identical assets or liabilities in active markets accessible by the Company at the measurement date.   Level 2 inputs that are observable in the marketplace other than those inputs classified as Level 1.   Level 3 inputs that are unobservable in the marketplace and significant to the valuation.   The Company has no assets or liabilities that are required to be carried at fair value. Accounts payable and related party payables have fair values that approximate the carrying value due to the short term nature of these instruments.   Recent Accounting Pronouncements   Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not, or are not believed by management to, have a material impact on the Company's present or future consolidated financial statements.   Net loss per common share   Net loss per share is calculated in accordance with FASB ASC Topic 260 (formerly SFAS No. 128, Earnings Per Share). The weighted-average number of common shares outstanding during each period is used to compute basic loss per share. Diluted loss per share is computed using the weighted average number of shares and dilutive potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised. Basic net loss per common share is based on the weighted average number of shares of common stock outstanding during the periods presented. The Company had 84,668,400 common stock equivalents that were excluded from earnings per share due to the anti-dilutive nature.

We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. Pursuant to FASB ASC Topic 740, when it is more likely than not that a tax asset cannot be realized through future income, the Company must provide an allowance for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carry-forwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carry-forward period.   The sources and tax effects of the temporary differences for the periods presented are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Net operating loss carry forward</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">748,640</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">318,139</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Applicable Canadian Federal and Provincial tax rates</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">26.5</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">26.5</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Deferred tax asset</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">198,390</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">84,307</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Valuation allowance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(198,390</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(84,307</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Net deferred tax asset</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   This represents an increase in the net operating loss carry forward of $430,501 and $19,869 for the years ended December 31, 2015 and 2014. A reconciliation of income taxes computed at the United States federal statutory rate of 35% to the income tax recorded is as follows:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Tax benefit at United States Federal statutory rate (35%)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">220,538</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">65,221</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Differences in U.S. and Canadian tax rates on provision</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(36,592</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(15,839</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Non-deductible losses-prepaids</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(69,862</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(42,428</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Increase in valuation allowance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(114,083</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(6,954</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Income tax provision</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   This represents an increase in the valuation allowance of $114,083 and $6,954 for the years ended December 31, 2015 and 2014. The Company did not pay any income taxes during the years ended December 31, 2015 or 2014, or since inception.    The net federal operating loss carry forward will begin to expire in 2026.  This carry forward may be limited upon the consummation of a business combination under IRC Section 381. Tax years commencing in 2012 remain open for examination by the IRS, where applicable.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Net operating loss carry forward</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">748,640</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">318,139</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Applicable Canadian Federal and Provincial tax rates</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">26.5</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">26.5</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Deferred tax asset</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">198,390</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">84,307</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Valuation allowance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(198,390</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(84,307</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Net deferred tax asset</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Tax benefit at United States Federal statutory rate (35%)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">220,538</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">65,221</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Differences in U.S. and Canadian tax rates on provision</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(36,592</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(15,839</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Non-deductible losses-prepaids</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(69,862</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(42,428</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Increase in valuation allowance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(114,083</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(6,954</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Income tax provision</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

81170

120000

1.00

5000000

100000 120000 0 120000 138830000

748640

318139

198390

84307

-198390

-84307

-6954

-114083

-42428 -69862

-15839

-36592

65221

220538

430501

19869

0.35

6954

114083

2026 100000 0.265 0.265 The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern.  This contemplates the realization of assets and the liquidation of liabilities in the normal course of business.  Currently, the Company has no cash, no material assets, accumulated losses of $3,428,812, a working capital deficit of $118,891, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern.  The Company will be dependent upon the raising of additional capital through placement of our common stock in order to implement its business plan, or merge with an operating company.  There can be no assurance that the Company will be successful in either situation in order to continue as a going concern.  The officers and directors have committed to advancing certain operating costs of the Company.

10249

EX-101.SCH 5 hcre-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Excess Cost of Prepaid Royalties Over Value link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Excess Cost of Prepaid Royalties Over Value (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hcre-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 hcre-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 hcre-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Preferred Stock Equity Components [Axis] Common Stock Additional Paid-In Capital Other Comprehensive Income Treasury Stock Accumulated Deficit Noteholder 1 [Member] Debt Instrument [Axis] Noteholder 2 [Member] Series A convertible preferred Stock [Member] Class of Stock [Axis] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets Cash Prepaid expenses Total current assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities Dividends payable Related party payables Current notes payables Related party convertible notes payable, net of discounts $10,249 and $0 Convertible notes payable, net of discounts $12,835 and $0 Total current liabilities Stockholders' deficit Series A convertible preferred stock, $1.00 par value; 5,000,000 shares authorized, 81,170 and 120,000 and shares issued and outstanding at December 31, 2015 and 2014 Common stock, $0.001 par value; 275,000,000 shares authorized; 142,162,211 and 3,136,000 issued; 141,782,211 and 2,756,000 outstanding at December 31, 2015 and 2014 Additional paid in capital Other comprehensive income Treasury stock, 380,000 shares Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Convertible notes payable, net of discounts Convertible notes payable, net of discounts Convertible preferred stock; par value Convertible preferred stock; shares authorized Convertible preferred stock; shares issued Convertible preferred stock; shares outstanding Common stock; par value Common stock; shares authorized Common stock; shares issued Common stock; shares outstanding Treasury stock shares Statements Of Operations Revenue Operating expenses General and administrative Professional fees Total operating expenses Other income (expense) Other income Interest expense Excess cost of prepaid royalties over value Total other income (expense) Net loss Preferred stock dividends payable Net loss attributable to common shareholders Basic and diluted loss per common share Weighted average shares outstanding Beginning Balance, Shares Beginning Balance, Amount Preferred shares issued for prepayment of royalty, Shares Preferred shares issued for prepayment of royalty, Amount Treasury stock exchanged for asset, Shares Treasury stock exchanged for asset, Amount Conversion of preferred shares to common shares, Shares Conversion of preferred shares to common shares, Amount Issuance of common shares for rounding in stock split, Shares Issuance of common shares for rounding in stock split, Amount Recession of common shares, Shares Recession of common shares, Amount Common stock issued for cash, Shares Common stock issued for cash, Amount Beneficial conversion features recorded as debt discounts Dividend declared on preferred stock Net loss Ending Balance, Shares Ending Balance, Amount Statements Of Cash Flows Cash flows from operating activities Net loss from operations Adjustments to reconcile net loss to net cash used in operating activities Excess cost of prepaid royalties over value Gain on sale of intangible asset for treasury stock Note payable entered into for professional fees Amortization of debt discounts Expenses paid on behalf of company by related parties Changes in operating assets and liabilities Prepaid expenses Accounts payable and accrued liabilities Net cash provided by (used in) operating activities Net cash used in investing activities Cash flows from financing activities Proceeds from convertible notes payable Repayments of convertible notes payable Repayments of related party convertible notes payable Proceeds from sale of common stock Net cash provided by financing activities Net change in cash Cash at beginning of period Cash at end of period Supplemental cash flow information Cash paid for interest Cash paid for income taxes Non-cash investing and financing activities Preferred stock issued for prepaid royalties Related party convertible notes entered into in exchange for related party payable Notes to Financial Statements Note 1 - Nature of Business Note 2 - Significant Accounting Policies Note 3 - Stockholders' Equity Note 4 - Income Taxes Note 5 - Related Party Transactions Note 6 - Excess Cost of Prepaid Royalties Over Value Note 7 - Notes Payable Note 8 - Convertible Notes Payable Note 9 - Subsequent Events Significant Accounting Policies Policies Estimates Cash Income taxes Revenue Recognition Convertible debt Share Based Expenses Going concern Valuation of Investments in Securities and Securities at fair value – Definition and Hierarchy Recent Accounting Pronouncements Net loss per common share Income Taxes Tables Schedule of deferred income tax assets Schedule of income Taxes Convertible Notes Payable Tables Summary of the outstanding convertible notes payable Repayment of royalty to related party Repayment of royalty to related party value Series A convertible preferred stock; shares issued Series A convertible preferred stock; shares outstanding Recession of common shares Conversion of preferred shares to common shares Income Taxes Details Net operating loss carry forward Applicable Canadian Federal and Provincial tax rates Deferred tax asset Valuation allowance Net deferred tax asset Income Taxes Details 1 Tax benefit at United States Federal statutory rate (35%) Differences in U.S. and Canadian tax rates on provision Non-deductible losses-prepaids Increase in valuation allowance Income tax provision Income Taxes Details Narrative Net operating loss carryforwards United States federal statutory rate Net operating loss carryforwards, expiration date Valuation allowance Related Party Transactions Details Narrative Unamortized discount Accrued interest Proceeds from related party loans Related party payables Series A convertible preferred stock; par value Share issued Notes Payable Details Narrative Note payable entered into for professional fees Accrued interest Due Date Principal Discount Net Value Convertible Notes Payable Details Narrative Document And Entity Information custom:ExcessCostOfPrepaidRoyaltiesOverValue Notes to Financial Statements Assets, Current Assets Liabilities, Current Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity ConvertibleNotesPayableNetOfDiscounts1 Operating Expenses Interest Expense Other Expenses EX-101.PRE 9 hcre-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2015	May. 23, 2016
Document And Entity Information
Entity Registrant Name	HEMCARE HEALTH SERVICES INC.
Entity Central Index Key	0001420368
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	Yes
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 0
Entity Common Stock, Shares Outstanding		141,782,211
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2015

XML 11 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash	$ 20,334
Prepaid expenses	2,630
Total current assets	22,964
Total assets	22,964	$ 0
Current liabilities
Accounts payable and accrued liabilities	86,896	$ 67,665
Dividends payable	19,000
Related party payables	37,249	$ 37,249
Current notes payables	350,000
Related party convertible notes payable, net of discounts $10,249 and $0	385
Convertible notes payable, net of discounts $12,835 and $0	3,865
Total current liabilities	497,395	$ 104,914
Stockholders' deficit
Common stock, $0.001 par value; 275,000,000 shares authorized; 142,162,211 and 3,136,000 issued; 141,782,211 and 2,756,000 outstanding at December 31, 2015 and 2014	142,162	3,136
Additional paid in capital	2,556,665	2,377,270
Other comprehensive income	24	24
Treasury stock, 380,000 shares	(100)	(100)
Accumulated deficit	(3,254,352)	(2,605,244)
Total stockholders' deficit	(474,431)	(104,914)
Total liabilities and stockholders' deficit	22,964	0
Series A convertible preferred Stock [Member]
Stockholders' deficit
Series A convertible preferred stock, $1.00 par value; 5,000,000 shares authorized, 81,170 and 120,000 and shares issued and outstanding at December 31, 2015 and 2014	$ 81,170	$ 120,000

XML 12 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current liabilities
Convertible notes payable, net of discounts	$ 10,249	$ 0
Convertible notes payable, net of discounts	$ 12,835	$ 0
Stockholders' deficit
Convertible preferred stock; par value	$ 1.00	$ 1.00
Common stock; par value	$ 0.001	$ 0.001
Common stock; shares authorized	275,000,000	275,000,000
Common stock; shares issued	142,162,211	3,136,000
Common stock; shares outstanding	141,782,211	2,756,000
Treasury stock shares	380,000	380,000
Series A convertible preferred Stock [Member]
Stockholders' deficit
Convertible preferred stock; par value	$ 1.00	$ 1.00
Convertible preferred stock; shares authorized	5,000,000	5,000,000
Convertible preferred stock; shares issued	81,170	120,000
Convertible preferred stock; shares outstanding	81,170	120,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Statements Of Operations
Revenue
Operating expenses
General and administrative	$ 23,977
Professional fees	375,284	$ 26,340
Total operating expenses	399,261	26,340
Other income (expense)
Other income	937	$ 100
Interest expense	(32,177)
Excess cost of prepaid royalties over value	(199,607)	$ (160,105)
Total other income (expense)	(230,847)	(160,005)
Net loss	(630,108)	$ (186,345)
Preferred stock dividends payable	(19,000)
Net loss attributable to common shareholders	$ (649,108)	$ (186,345)
Basic and diluted loss per common share	$ (0.01)	$ (0.06)
Weighted average shares outstanding	87,783,992	2,932,578

XML 14 R5.htm IDEA: XBRL DOCUMENT

Statement of Changes in Stockholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Other Comprehensive Income	Treasury Stock	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2013		3,136,000
Beginning Balance, Amount at Dec. 31, 2013		$ 3,136	$ 2,337,165	$ 24		$ (2,418,899)	$ (78,574)
Preferred shares issued for prepayment of royalty, Shares	120,000
Preferred shares issued for prepayment of royalty, Amount	$ 120,000		$ 40,105				160,105
Treasury stock exchanged for asset, Shares		(380,000)
Treasury stock exchanged for asset, Amount					$ (100)		$ (100)
Dividend declared on preferred stock
Net loss						$ (186,345)	$ (186,345)
Ending Balance, Shares at Dec. 31, 2014	120,000	2,756,000
Ending Balance, Amount at Dec. 31, 2014	$ 120,000	$ 3,136	$ 2,377,270	$ 24	$ (100)	$ (2,605,244)	(104,914)
Preferred shares issued for prepayment of royalty, Shares	100,000
Preferred shares issued for prepayment of royalty, Amount	$ 100,000		$ 99,607				$ 199,607
Conversion of preferred shares to common shares, Shares	(138,830)	138,830,000
Conversion of preferred shares to common shares, Amount	$ (138,830)	$ 138,830
Issuance of common shares for rounding in stock split, Shares		26,211
Issuance of common shares for rounding in stock split, Amount		$ 26	$ (26)
Recession of common shares, Shares		(730,000)
Recession of common shares, Amount		$ (730)	730
Common stock issued for cash, Shares		900,000
Common stock issued for cash, Amount		$ 900	44,100				$ 45,000
Beneficial conversion features recorded as debt discounts			$ 34,984				34,984
Dividend declared on preferred stock						$ (19,000)	(19,000)
Net loss						(630,108)	(630,108)
Ending Balance, Shares at Dec. 31, 2015	81,170	141,782,211
Ending Balance, Amount at Dec. 31, 2015	$ 81,170	$ 142,162	$ 2,556,665	$ 24	$ (100)	$ (3,254,352)	$ (474,431)

XML 15 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss from operations	$ (630,108)	$ (186,345)
Adjustments to reconcile net loss to net cash used in operating activities
Excess cost of prepaid royalties over value	$ 199,607	160,105
Gain on sale of intangible asset for treasury stock		$ (100)
Note payable entered into for professional fees	$ 350,000
Amortization of debt discounts	11,900
Expenses paid on behalf of company by related parties	15,784	$ 18,035
Changes in operating assets and liabilities
Prepaid expenses	(2,630)	800
Accounts payable and accrued liabilities	19,231	$ 7,505
Net cash provided by (used in) operating activities	$ (36,216)
Net cash used in investing activities
Cash flows from financing activities
Proceeds from convertible notes payable	$ 19,700
Repayments of convertible notes payable	(3,000)
Repayments of related party convertible notes payable	(5,150)
Proceeds from sale of common stock	45,000
Net cash provided by financing activities	56,550
Net change in cash	$ 20,334
Cash at beginning of period
Cash at end of period	$ 20,334
Supplemental cash flow information
Cash paid for interest
Cash paid for income taxes
Non-cash investing and financing activities
Preferred stock issued for prepaid royalties	$ 100,000	$ 120,000
Related party convertible notes entered into in exchange for related party payable	15,784
Note payable entered into for professional fees	$ 350,000

XML 16 R7.htm IDEA: XBRL DOCUMENT

Nature of Business

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 1 - Nature of Business

XML 17 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 2 - Significant Accounting Policies

Estimates

Cash

Income taxes

Revenue Recognition

Convertible debt

Share Based Expenses

Going concern

Valuation of Investments in Securities and Securities at fair value – Definition and Hierarchy

Level 1 – unadjusted quoted prices for identical assets or liabilities in active markets accessible by the Company at the measurement date.

Level 2 – inputs that are observable in the marketplace other than those inputs classified as Level 1.

Level 3 – inputs that are unobservable in the marketplace and significant to the valuation.

Recent Accounting Pronouncements

Net loss per common share

XML 18 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 3 - Stockholders' Equity

Series A Convertible Preferred Stock

As discussed in the 8K filed with the SEC on June 29, 2014, during the year ended December 31, 2014, the Company amended its articles of incorporation to designate the previously authorized series A preferred stock to series A convertible preferred stock. The preferred series A 12% convertible shares have a par value of $1, entitle holder to one vote and accrue dividends at 12% per year, paid quarterly. At the option of the holder, the stock can be converted into shares of the Company's common stock. The number of shares to be issued will be determined by dividing the amount of the Series A shares being converted by $0.001.

The excess of the value of the preferred shares issued in excess of the value of the prepaid royalties has been expensed as a financing cost.

Common Stock

On March 2, 2015, the Company effected a 1:50 reverse stock split. The effects of the reverse split are shown retroactively in these financial statements.

During the year ended December 31, 2015, the Company issued 138,830,000 common shares from the conversion of 138,830 shares of Series A Preferred Stock.

There were 142,162,211 and 3,136,000 common shares issued and 141,782,211 and 2,756,000 outstanding (post-split) at December 31, 2015 and 2014, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 19 R10.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 4 - Income Taxes

The sources and tax effects of the temporary differences for the periods presented are as follows:

	December 31, 2015			December 31, 2014
Net operating loss carry forward	$	748,640		$	318,139
Applicable Canadian Federal and Provincial tax rates		26.5	%		26.5	%
Deferred tax asset		198,390			84,307
Valuation allowance		(198,390	)		(84,307	)
Net deferred tax asset	$	-		$	-

	December 31, 2015			December 31, 2014

Tax benefit at United States Federal statutory rate (35%)	$	220,538		$	65,221
Differences in U.S. and Canadian tax rates on provision		(36,592	)		(15,839	)
Non-deductible losses-prepaids		(69,862	)		(42,428	)
Increase in valuation allowance		(114,083	)		(6,954	)
Income tax provision	$	-		$	-

XML 20 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 5 - Related Party Transactions

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Excess Cost of Prepaid Royalties Over Value

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 6 - Excess Cost of Prepaid Royalties Over Value

XML 22 R13.htm IDEA: XBRL DOCUMENT

Notes Payable	12 Months Ended
Notes Payable	Dec. 31, 2015
Notes to Financial Statements
Note 7 - Notes Payable	During the year ended December 31, 2015, the Company entered into a note payable with an unrelated party as a settlement for payment of consulting services provided valued at $350,000. The note carries interest of 9% compounded annually and is due on November 19, 2016. There was $350,000 of principal and $19,504 of accrued interest due as of December 31, 2015. Accrued interest payable is included in "accounts payable and accrued liabilities" on the balance sheet.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

12 Months Ended

Dec. 31, 2015

Notes to Financial Statements

Note 8 - Convertible Notes Payable

	Due Date	Principal		Discount			Net Value

Noteholder 1	9/1/2016	$	16,700	$	(12,835	)	$	3,865
Total		$	16,700	$	(12,835	)	$	3,865

XML 24 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2015
Notes to Financial Statements
Note 9 - Subsequent Events	We have evaluated subsequent events through the date of this filing and determined there are no additional events to disclose.

XML 25 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2015
Significant Accounting Policies Policies
Estimates	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash	For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2015 or 2014.
Income taxes	Income taxes are provided for using the liability method of accounting in accordance with FASB ASC Topic 740 (formally SFAS No. 109 "Accounting for Income Taxes"). A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and rates on the date of enactment.
Revenue Recognition	Revenue is recognized when persuasive evidence of an agreement exists, the price is fixed or determinable, goods are delivered or services performed and collectability is reasonably assured. The Company did not generate any revenues during the years ended December 31, 2015 or 2014.
Convertible debt	The Company records a beneficial conversion feature related to the issuance of convertible debts that have conversion features at fixed or adjustable rates. The beneficial conversion feature for the convertible instruments is recognized and measured by allocating a portion of the proceeds as an increase in additional paid-in capital and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features. The beneficial conversion feature will be accreted by recording additional non-cash interest expense over the expected life of the convertible notes.
Share Based Expenses	The Company complies with FASB ASC Topic 718 Compensation—Stock Compensation, which establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that is based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. FASB ASC Topic 718 primarily focuses on accounting for transactions in which an entity obtains employee services in share-based payment transactions. This statement requires a public entity to expense the cost of employee services received in exchange for an award of equity instruments. This statement also provides guidance on valuing and expensing these awards, as well as disclosure requirements of these equity arrangements. The Company adopted FASB ASC Topic 718 upon formation of the Company and expenses share based costs in the period incurred.
Going concern	The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. Currently, the Company has no cash, no material assets, accumulated losses of $3,428,812, a working capital deficit of $118,891, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern. The Company will be dependent upon the raising of additional capital through placement of our common stock in order to implement its business plan, or merge with an operating company. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The officers and directors have committed to advancing certain operating costs of the Company.
Valuation of Investments in Securities and Securities at fair value – Definition and Hierarchy	FASB ASC 820-10-15 defines fair value, thereby eliminating inconsistencies in guidance found in various prior accounting pronouncements, and increases disclosures surrounding fair value calculations. FASB ASC 820-10-15 establishes a three-tiered fair value hierarchy that prioritizes inputs to valuation techniques used in fair value calculations. The three levels of inputs are defined as follows: Level 1 – unadjusted quoted prices for identical assets or liabilities in active markets accessible by the Company at the measurement date. Level 2 – inputs that are observable in the marketplace other than those inputs classified as Level 1. Level 3 – inputs that are unobservable in the marketplace and significant to the valuation. The Company has no assets or liabilities that are required to be carried at fair value. Accounts payable and related party payables have fair values that approximate the carrying value due to the short term nature of these instruments.
Recent Accounting Pronouncements	Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not, or are not believed by management to, have a material impact on the Company's present or future consolidated financial statements.
Net loss per common share	Net loss per share is calculated in accordance with FASB ASC Topic 260 (formerly SFAS No. 128, Earnings Per Share). The weighted-average number of common shares outstanding during each period is used to compute basic loss per share. Diluted loss per share is computed using the weighted average number of shares and dilutive potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised. Basic net loss per common share is based on the weighted average number of shares of common stock outstanding during the periods presented. The Company had 84,668,400 common stock equivalents that were excluded from earnings per share due to the anti-dilutive nature.

XML 26 R17.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Taxes Tables

Schedule of deferred income tax assets

	December 31, 2015			December 31, 2014
Net operating loss carry forward	$	748,640		$	318,139
Applicable Canadian Federal and Provincial tax rates		26.5	%		26.5	%
Deferred tax asset		198,390			84,307
Valuation allowance		(198,390	)		(84,307	)
Net deferred tax asset	$	-		$	-

Schedule of income Taxes

	December 31, 2015			December 31, 2014

Tax benefit at United States Federal statutory rate (35%)	$	220,538		$	65,221
Differences in U.S. and Canadian tax rates on provision		(36,592	)		(15,839	)
Non-deductible losses-prepaids		(69,862	)		(42,428	)
Increase in valuation allowance		(114,083	)		(6,954	)
Income tax provision	$	-		$	-

XML 27 R18.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Tables)

12 Months Ended

Dec. 31, 2015

Convertible Notes Payable Tables

Summary of the outstanding convertible notes payable

	Due Date	Principal		Discount			Net Value

Noteholder 1	9/1/2016	$	16,700	$	(12,835	)	$	3,865
Total		$	16,700	$	(12,835	)	$	3,865

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)	12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Dividends payable	$ 19,000
Conversion of preferred shares to common shares, Amount
Common stock issued for cash, Amount	$ 45,000
Common stock; shares authorized	275,000,000	275,000,000
Common stock; shares issued	142,162,211	3,136,000
Common stock; shares outstanding	141,782,211	2,756,000
Common Stock
Recession of common shares	(730,000)
Conversion of preferred shares to common shares, Amount	$ 138,830
Issuance of common shares for rounding in stock split, Shares	26,211
Common stock issued for cash, Amount	$ 900
Common stock issued for cash, Shares	900,000
Series A convertible preferred Stock [Member]
Repayment of royalty to related party	$ 100,000	$ 120,000
Repayment of royalty to related party value	$ 0	$ 120,000
Series A convertible preferred stock; shares issued	81,170	120,000
Series A convertible preferred stock; shares outstanding	81,170	120,000
Conversion of preferred shares to common shares	138,830,000

XML 29 R20.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes Details
Net operating loss carry forward	$ 748,640	$ 318,139
Applicable Canadian Federal and Provincial tax rates	26.50%	26.50%
Deferred tax asset	$ 198,390	$ 84,307
Valuation allowance	$ (198,390)	$ (84,307)
Net deferred tax asset

XML 30 R21.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 1) - USD ($)	12 Months Ended
Income Taxes (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes Details 1
Tax benefit at United States Federal statutory rate (35%)	$ 220,538	$ 65,221
Differences in U.S. and Canadian tax rates on provision	(36,592)	(15,839)
Non-deductible losses-prepaids	(69,862)	(42,428)
Increase in valuation allowance	$ (114,083)	$ (6,954)
Income tax provision

XML 31 R22.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes Details Narrative
Net operating loss carryforwards	$ 430,501	$ 19,869
United States federal statutory rate	35.00%
Net operating loss carryforwards, expiration date	2026
Valuation allowance	$ 114,083	$ 6,954

XML 32 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Related Party Transactions Details Narrative
Unamortized discount	$ 10,249	$ 0
Accrued interest	10,634
Proceeds from related party loans	5,535
Related party payables	360
Expenses paid on behalf of company by related parties	$ 15,784	$ 18,035

XML 33 R24.htm IDEA: XBRL DOCUMENT

Excess Cost of Prepaid Royalties Over Value (Details Narrative) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Series A convertible preferred stock; par value	$ 1.00	$ 1.00
Series A convertible preferred Stock [Member]
Series A convertible preferred stock; par value	$ 1.00	$ 1.00
Share issued	100,000

XML 34 R25.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative)	12 Months Ended
Notes Payable (Details Narrative)	Dec. 31, 2015 USD ($)
Notes Payable Details Narrative
Note payable entered into for professional fees	$ 350,000
Accrued interest	$ 19,504

XML 35 R26.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - USD ($)	12 Months Ended
Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Principal	$ 16,700
Discount	(12,835)
Net Value	$ 3,865
Noteholder 1 [Member]
Due Date	9/1/2016
Principal	$ 16,700
Discount	(12,835)
Net Value	$ 3,865

XML 36 R27.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
Convertible Notes Payable (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Convertible Notes Payable Details Narrative
Proceeds from convertible notes payable	$ 19,700

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 42 137 1 false 8 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://hemcarehealthservicesinc/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://hemcarehealthservicesinc/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://hemcarehealthservicesinc/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://hemcarehealthservicesinc/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statement of Changes in Stockholders' Deficit Sheet http://hemcarehealthservicesinc/role/StatementOfChangesInStockholdersDeficit Statement of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows Sheet http://hemcarehealthservicesinc/role/StatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business Sheet http://hemcarehealthservicesinc/role/NatureOfBusiness Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Significant Accounting Policies Sheet http://hemcarehealthservicesinc/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Stockholders' Equity Sheet http://hemcarehealthservicesinc/role/StockholdersEquity Stockholders' Equity Notes 9 false false R10.htm 00000010 - Disclosure - Income Taxes Sheet http://hemcarehealthservicesinc/role/IncomeTaxes Income Taxes Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://hemcarehealthservicesinc/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Excess Cost of Prepaid Royalties Over Value Sheet http://hemcarehealthservicesinc/role/ExcessCostOfPrepaidRoyaltiesOverValue Excess Cost of Prepaid Royalties Over Value Notes 12 false false R13.htm 00000013 - Disclosure - Notes Payable Notes http://hemcarehealthservicesinc/role/NotesPayable Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Convertible Notes Payable Notes http://hemcarehealthservicesinc/role/ConvertibleNotesPayable Convertible Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://hemcarehealthservicesinc/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://hemcarehealthservicesinc/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://hemcarehealthservicesinc/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Income Taxes (Tables) Sheet http://hemcarehealthservicesinc/role/IncomeTaxesTables Income Taxes (Tables) Tables http://hemcarehealthservicesinc/role/IncomeTaxes 17 false false R18.htm 00000018 - Disclosure - Convertible Notes Payable (Tables) Notes http://hemcarehealthservicesinc/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://hemcarehealthservicesinc/role/ConvertibleNotesPayable 18 false false R19.htm 00000019 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://hemcarehealthservicesinc/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://hemcarehealthservicesinc/role/StockholdersEquity 19 false false R20.htm 00000020 - Disclosure - Income Taxes (Details) Sheet http://hemcarehealthservicesinc/role/IncomeTaxesDetails Income Taxes (Details) Details http://hemcarehealthservicesinc/role/IncomeTaxesTables 20 false false R21.htm 00000021 - Disclosure - Income Taxes (Details 1) Sheet http://hemcarehealthservicesinc/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://hemcarehealthservicesinc/role/IncomeTaxesTables 21 false false R22.htm 00000022 - Disclosure - Income Taxes (Details Narrative) Sheet http://hemcarehealthservicesinc/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://hemcarehealthservicesinc/role/IncomeTaxesTables 22 false false R23.htm 00000023 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://hemcarehealthservicesinc/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://hemcarehealthservicesinc/role/RelatedPartyTransactions 23 false false R24.htm 00000024 - Disclosure - Excess Cost of Prepaid Royalties Over Value (Details Narrative) Sheet http://hemcarehealthservicesinc/role/ExcessCostOfPrepaidRoyaltiesOverValueDetailsNarrative Excess Cost of Prepaid Royalties Over Value (Details Narrative) Details http://hemcarehealthservicesinc/role/ExcessCostOfPrepaidRoyaltiesOverValue 24 false false R25.htm 00000025 - Disclosure - Notes Payable (Details Narrative) Notes http://hemcarehealthservicesinc/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://hemcarehealthservicesinc/role/NotesPayable 25 false false R26.htm 00000026 - Disclosure - Convertible Notes Payable (Details) Notes http://hemcarehealthservicesinc/role/ConvertibleNotesPayableDetails Convertible Notes Payable (Details) Details http://hemcarehealthservicesinc/role/ConvertibleNotesPayableTables 26 false false R27.htm 00000027 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://hemcarehealthservicesinc/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://hemcarehealthservicesinc/role/ConvertibleNotesPayableTables 27 false false All Reports Book All Reports hcre-20151231.xml hcre-20151231.xsd hcre-20151231_cal.xml hcre-20151231_def.xml hcre-20151231_lab.xml hcre-20151231_pre.xml true true ZIP 43 0001477932-16-010545-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-16-010545-xbrl.zip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

	·	that a broker or dealer approve a person's account for transactions in penny stocks;
	·	the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased; and
	·	that a broker or dealer provide certain detailed market information about the market for the applicable company's securities.

	·	sets forth the basis on which the broker or dealer made the suitability determination; and
	·	that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

	·	Policies and Procedures for the Financial Close and Reporting Process — Currently there are no policies or procedures that clearly define the roles in the financial close and reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Failure to have such policies and procedures in place amounts to a material weakness to the Company's internal controls over its financial reporting processes.
	·	Representative with Financial Expertise — For the year ending December 31, 2015, the Company did not have a representative with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures of the Company. Failure to have a representative with such knowledge and expertise amounts to a material weakness to the Company's internal controls over its financial reporting processes.
	·	Adequacy of Accounting Systems at Meeting Company Needs — The accounting system in place at the time of the assessment lacks the ability to provide high quality financial statements from within the system, and there were no procedures in place or built into the system to ensure that all relevant information is secure, identified, captured, processed, and reported within the accounting system. Failure to have an adequate accounting system with procedures to ensure the information is secure and accurately recorded and reported amounts to a material weakness to the Company's internal controls over its financial reporting processes.
	·	Segregation of Duties — Management has identified a significant general lack of definition and segregation of duties throughout the financial reporting processes. Due to the pervasive nature of this issue, the lack of adequate definition and segregation of duties amounts to a material weakness to the Company's internal controls over its financial reporting processes.

	·	The Officers and Directors;
	·	Any person proposed as a nominee for election as a director;
	·	Any other person who beneficially owns, directly or indirectly, shares carrying more than 5% of the voting rights attached to the outstanding shares of common stock;
	·	Any relative or spouse of any of the foregoing persons who have the same house as such person.

EXHIBIT NUMBER		DESCRIPTION

3.1		Articles of Incorporation
3.2		By-Laws
23.1		Consent of Accountant
31.1		SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
32.1		CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
101		XBRL Interactive Data Files